AstraZeneca PLC (AZNCF) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - General secteur d'activité. Le siège social de l'entreprise est situé à Cambridge, United Kingdom. Le PDG actuel est Pascal Claude Roland Soriot.
AZNCF a date d'introduction en bourse 2009-02-13, 94,300 employés à temps plein, cotée sur le Other OTC, une capitalisation boursière de $294.4B.
AstraZeneca PLC is a global biopharmaceutical company headquartered in Cambridge, United Kingdom, specializing in the discovery, development, manufacturing, and commercialization of prescription medicines. The company maintains a diverse portfolio spanning oncology, cardiovascular and metabolic diseases, respiratory and immunology, and rare diseases, with marketed products including Tagrisso, Lynparza, and Imfinzi for cancer; Farxiga and Crestor for heart and metabolic conditions; Symbicort and Fasenra for respiratory care; and Soliris for rare diseases, among many others. AstraZeneca also markets vaccines and treatments for respiratory syncytial virus, influenza, COVID-19, and other therapeutic areas. The company distributes its medicines through a global network of physicians and representatives across Europe, the Americas, Asia, Africa, and Australasia. AstraZeneca maintains strategic collaborations with leading pharmaceutical and biotechnology partners, including Regeneron Pharmaceuticals for obesity treatments and Ionis Pharmaceuticals for antisense therapies in development.
